Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aditxt Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADTX
Nasdaq
8731
https://aditxt.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aditxt Inc
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
- Apr 2nd, 2024 12:30 pm
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
- Mar 27th, 2024 12:36 pm
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
- Mar 7th, 2024 12:54 pm
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
- Feb 1st, 2024 1:00 pm
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
- Jan 30th, 2024 1:30 pm
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
- Jan 8th, 2024 1:30 pm
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
- Jan 5th, 2024 1:30 pm
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
- Jan 2nd, 2024 1:30 pm
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
- Dec 29th, 2023 10:07 pm
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
- Dec 12th, 2023 1:30 pm
Aditxt, Inc. to Present at 8th Annual Dawson James Conference
- Oct 6th, 2023 12:00 pm
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
- Oct 5th, 2023 12:00 pm
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Sep 21st, 2023 1:35 pm
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
- Sep 8th, 2023 11:05 am
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
- Sep 6th, 2023 8:30 pm
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
- Aug 31st, 2023 11:00 pm
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
- Aug 18th, 2023 11:02 am
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
- Aug 17th, 2023 8:12 pm
Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics
- Jun 20th, 2023 11:49 am
Aditxt First Quarter 2023 Earnings: US$1.31 loss per share (vs US$6.80 loss in 1Q 2022)
- May 19th, 2023 10:10 am
Scroll